Appearance
Battle Cards
Every claim below is sourced and verbatim-ready. The "Don't Say" column is more important than the "Say" column.
What NOT to Claim
| Don't Say | Why | Say Instead |
|---|---|---|
| "No deaths" (cohort-specific) | Two patients died (Nov-Dec 2025). Cohort-specific claims from VARIPURE/VARISURE are now outdated. | "Best death rate in PFA — 0.75 per 10K. All investigated." |
| "FARAPULSE is dangerous" | 500,000+ procedures. Physicians trust it. 0.02% death rate. | "91 deaths, 56% with unknown root cause. 16 from design flaws." |
| "Affera is hype" | 300%+ revenue growth. Physicians who've used it like it. | "32 design flaws, 63 electrical failures, 7 software bugs in year one." |
| "PFA is safer than RF" | PFA has class-wide risks (hemolysis 9%, coronary narrowing). | "PFA eliminates esophageal fistula. We offer both PFA and RF." |
| "Volt is too new" | IDE data (84.2% PAF, zero hemolysis) is strong. | "392 patients vs our 40,000. Let's see what real-world use shows." |
What You CAN Claim Now
| Claim | Data | Source |
|---|---|---|
| "Lowest death rate in PFA" | 0.75 per 10K vs 1.8 FARAPULSE, 3.7 PulseSelect | FDA MAUDE + company-reported volumes |
| "Lowest mfg defect rate" | 3.0 per 10K vs 5.7 FARAPULSE, 44.3 PulseSelect | FDA MAUDE + company-reported volumes |
| "0.22% stroke rate post-correction" | 6,811 patients after IFU update | 2026 AF Symposium data |
| "87.9% same-day discharge" | VARISURE Safety Survey, 850 procedures | 2026 AF Symposium |
| "Every death investigated" | 3/3 MAUDE death reports have detailed follow-up | FDA MAUDE narratives |
| "Only PFA + RF + mapping" | No competitor covers 100% of EP cases | Product portfolio fact |
vs FARAPULSE (Boston Scientific)
"They Have 500,000 Procedures"
"More procedures, more data — fair. And at scale, their death rate is 1.8 per 10K. Ours is 0.75. More than half their deaths have unknown root cause. Every one of ours has a full investigation. More procedures should mean better accountability, not less."
"VARIPULSE Had a Class I Recall"
"We found a 3% stroke rate in 132 patients. Paused immediately. Updated the protocol. 0.22% stroke rate in 6,811 patients since. FARAWAVE was recalled for the same signal — Class II, not Class I. They didn't pause."
"FARAPULSE Has MANIFEST-US"
"MANIFEST-US is good data — 41,968 patients. We agree PFA is safe. Our real-world data shows the same: 87.9% same-day discharge, 0.22% neurovascular events. We're building our own registry at 40,000 procedures."
"BSC Just Got Farapoint Approved"
"Farapoint gives BSC a focal catheter — something they've lacked. But it's brand new, limited release, no outcome data. We have QDOT MICRO for focal RF and VARIPULSE for PFA. We've had both for over a year."
BSC's Q4 Weakness
BSC missed Q4 EP consensus by $33M. Stock dropped 18% on Feb 4, 2026. BTIG lowered price target from $132 to $110.
"Boston Scientific's EP growth is slowing. Their easy adoption phase is over. The question for your lab is whether to lock into a platform that's plateauing or evaluate what's next."
For competitive evaluations only — don't lead with stock price. Use when an account is mid-evaluation and BSC is the incumbent.
vs Affera / Sphere-9 (Medtronic)
"Affera Replaces CARTO"
"For simple AF, Affera works. For complex cases, redos, multi-catheter workflows, training — CARTO is the only proven platform. 20 years of evidence, 4 design flaws. Affera has 32 design flaws, 63 electrical failures, and 7 software bugs in year one."
Next step: Offer a case observation at a site running both. Let the physician compare workflows.
"Affera Is Dual Energy"
"Affera does PFA and RF in one catheter. But when our separate QDOT MICRO does RF, it has 20 years of ablation physics data behind it. When Affera's single catheter fails electrically — and 63 have — you lose both mapping and ablation."
"Medtronic PFA Is Growing 300%"
"Their growth is real. Most of it is Affera cannibalizing PulseSelect — PulseSelect dropped 74% in 6 months. Their own physicians are switching away from their first PFA product because of 44 mfg defects per 10K procedures."
vs Abbott (Volt PFA)
"Abbott Has PFA Now"
"Volt launched in December. 84% PAF effectiveness in 392 patients is promising. But at 40,000 procedures, we know our safety profile. At 392, they know their IDE. First MAUDE data will appear Q1-Q2 2026."
"Volt Has Conscious Sedation"
"Conscious sedation is a genuine advantage for ASCs. If your practice is moving to ASC-based ablation, Volt's sedation profile is worth evaluating. We're working on our ASC solution. For hospital labs doing complex cases, we're the only platform that covers PFA, RF, and mapping."
Don't dismiss conscious sedation — physicians see it as real innovation. Acknowledge it, redirect to where VARIPULSE wins.
Handling Objections
| Objection | Response |
|---|---|
| "3 deaths" | "3 MAUDE reports, 2 patients. All investigated. FARAPULSE: 91, 56% unknown root cause." |
| "Class I recall" | "Proactive pause. 0.22% stroke in 6,811 patients post-update." |
| "14x microemboli" | "Updated IFU. Zero strokes in 6,811 post-update patients." |
| "Small sample" | "40,000 procedures. Best death rate and mfg defect rate in the category." |
| "FARAPULSE dominance" | "91 deaths, growth stalling (missed Q4 by $33M). Best rates are ours now." |
| "Affera threat" | "32 design flaws, 63 electrical failures in year one. Fast growth, immature product." |
| "No ASC play" | "87.9% same-day discharge. CMS just approved at $20,512. Working on it." |
| "Abbott Volt" | "Strong IDE. 392 patients. Let's see real-world data before comparing." |
| "No outcomes registry" | "Fair. We're building one. At 40K procedures, we have the volume." |
All competitive claims sourced from FDA adverse event data (2.99M events) with company-reported per-procedure rates. Clinical data from peer-reviewed studies and 2026 AF Symposium. See Method.